Numerai GP LLC Invests $372,000 in OrthoPediatrics Corp. (NASDAQ:KIDS)

Numerai GP LLC bought a new stake in shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 16,061 shares of the company's stock, valued at approximately $372,000. Numerai GP LLC owned approximately 0.07% of OrthoPediatrics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in KIDS. R Squared Ltd purchased a new stake in shares of OrthoPediatrics during the fourth quarter valued at approximately $48,000. KLP Kapitalforvaltning AS purchased a new position in shares of OrthoPediatrics in the fourth quarter worth $79,000. AlphaCentric Advisors LLC bought a new position in shares of OrthoPediatrics during the fourth quarter valued at $171,000. Wells Fargo & Company MN boosted its position in shares of OrthoPediatrics by 31.1% during the fourth quarter. Wells Fargo & Company MN now owns 9,853 shares of the company's stock valued at $228,000 after buying an additional 2,338 shares during the last quarter. Finally, HighTower Advisors LLC bought a new position in OrthoPediatrics during the fourth quarter valued at approximately $268,000. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at OrthoPediatrics

In related news, General Counsel Daniel J. Gerritzen sold 5,310 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $132,006.60. Following the completion of the transaction, the general counsel now directly owns 110,767 shares of the company's stock, valued at approximately $2,753,667.62. This represents a 4.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Fred Hite sold 6,443 shares of the company's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $160,172.98. Following the sale, the chief financial officer now owns 207,989 shares in the company, valued at $5,170,606.54. This represents a 3.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,732 shares of company stock valued at $589,978 in the last three months. 32.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on KIDS. Stifel Nicolaus decreased their target price on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, March 5th. Truist Financial decreased their price target on shares of OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Lake Street Capital began coverage on shares of OrthoPediatrics in a research report on Monday, April 7th. They set a "buy" rating and a $37.00 price objective for the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $42.00 target price on shares of OrthoPediatrics in a report on Thursday, May 8th. Finally, Piper Sandler cut their price target on OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, OrthoPediatrics presently has a consensus rating of "Moderate Buy" and an average target price of $35.83.

OrthoPediatrics Price Performance

Shares of NASDAQ KIDS traded down $0.50 during midday trading on Wednesday, reaching $22.39. The stock had a trading volume of 18,596 shares, compared to its average volume of 196,004. The company has a market capitalization of $543.79 million, a price-to-earnings ratio of -18.11 and a beta of 1.09. OrthoPediatrics Corp. has a 12-month low of $20.25 and a 12-month high of $35.99. The stock has a 50-day moving average of $22.77 and a 200-day moving average of $23.91. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.13). OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. The business had revenue of $52.41 million for the quarter, compared to the consensus estimate of $51.68 million. As a group, research analysts anticipate that OrthoPediatrics Corp. will post -0.93 EPS for the current fiscal year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.